methyl 7-ethyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylate 2,2-dioxide | 790254-39-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: methyl 7-ethyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylate 2,2-dioxide
• 英文别名: Methyl 3-ethyl-10,10-dioxo-10lambda6-thia-1,9-diazatricyclo[6.4.1.04,13]trideca-2,4(13),5,7-tetraene-6-carboxylate；methyl 3-ethyl-10,10-dioxo-10λ6-thia-1,9-diazatricyclo[6.4.1.04,13]trideca-2,4(13),5,7-tetraene-6-carboxylate
• CAS: 790254-39-6
• 化学式: C₁₄H₁₆N₂O₄S
• 分子量: 308.358
• InChiKey: UCRLSMANJISMFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  85.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 7-ethyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylate 2,2-dioxide 、 碘甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.53h， 以76%的产率得到methyl 7-ethyl-1-methyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylate 2,2-dioxide
  参考文献：
  名称：

  [EN] TRICYCLIC INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE
  [FR] DERIVES INDOLIQUES TRICYCLIQUES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

  摘要：

  本发明涉及具有Asp2（β-分泌酶、BACE1或Memapsin-2）抑制活性的新型酮化合物（I）的公式，其制备方法，包含它们的组合物以及它们在治疗由高β-淀粉样蛋白水平或β-淀粉样蛋白沉积特征的疾病，尤其是阿尔茨海默病中的用途。

  公开号：

  WO2006040148A1
• 作为产物：
  描述：

  methyl 7-[(ethenylsulfonyl)amino]-3-ethyl-1H-indole-5-carboxylate 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.08h， 以77%的产率得到methyl 7-ethyl-3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi]indole-9-carboxylate 2,2-dioxide
  参考文献：
  名称：

  [EN] TRICYCLIC INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE
  [FR] DERIVES INDOLIQUES TRICYCLIQUES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

  摘要：

  本发明涉及具有Asp2（β-分泌酶、BACE1或Memapsin-2）抑制活性的新型酮化合物（I）的公式，其制备方法，包含它们的组合物以及它们在治疗由高β-淀粉样蛋白水平或β-淀粉样蛋白沉积特征的疾病，尤其是阿尔茨海默病中的用途。

  公开号：

  WO2006040148A1

文献信息

• [EN] TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] DERIVES D'INDOLE TRICYCLIQUES ET LEUR UTILISATION DANS LE CADRE DU TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：GLAXO GROUP LTD

  公开号：WO2004094430A1

  公开（公告）日：2004-11-04

  The present invention relates to novel hydroxyethylamine compounds having Asp2 (β-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β- amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.

  本发明涉及具有Asp2（β-分泌酶、BACE1或Memapsin）抑制活性的新型羟乙基胺化合物，其制备方法，含有它们的组合物以及它们在治疗由β-淀粉样蛋白水平或β-淀粉样蛋白沉积物升高而特征化的疾病，特别是阿尔茨海默病中的用途。
• [EN] TRICYCLIC INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] DERIVES INDOLIQUES TRICYCLIQUES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：GLAXO GROUP LTD

  公开号：WO2006040148A1

  公开（公告）日：2006-04-20

  The present invention relates to novel ketone compounds of formula (I) having Asp2 (β-secretase, BACE1 or Memapsin-2) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β- amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.

  本发明涉及具有Asp2（β-分泌酶、BACE1或Memapsin-2）抑制活性的新型酮化合物（I）的公式，其制备方法，包含它们的组合物以及它们在治疗由高β-淀粉样蛋白水平或β-淀粉样蛋白沉积特征的疾病，尤其是阿尔茨海默病中的用途。
• Tricyclic indole derivatives and their use in the treatment of alzheimer's disease
  申请人：Demont Hubert Emmanuel

  公开号：US20060229302A1

  公开（公告）日：2006-10-12

  The present invention to novel hydroxyethylamine compounds having Asp2 (β-secretase, BACE1 or Memapsin) inhibitory activit, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β-amyloid levels or β-amyloid deposits, Particularly Alzheimer's disease.

  本发明涉及一种新型的羟乙基胺化合物，具有Asp2（β-分泌酶，BACE1或Memapsin）抑制活性，其制备方法，含有它们的组合物以及它们在治疗由升高的β-淀粉样蛋白水平或β-淀粉样蛋白沉积物所特征的疾病，特别是阿尔茨海默病中的应用。
• Second Generation of Hydroxyethylamine BACE-1 Inhibitors: Optimizing Potency and Oral Bioavailability
  作者：Nicolas Charrier、Brian Clarke、Leanne Cutler、Emmanuel Demont、Colin Dingwall、Rachel Dunsdon、Philip East、Julie Hawkins、Colin Howes、Ishrut Hussain、Phil Jeffrey、Graham Maile、Rosalie Matico、Julie Mosley、Alan Naylor、Alistair O’Brien、Sally Redshaw、Paul Rowland、Virginie Soleil、Kathrine J. Smith、Sharon Sweitzer、Pam Theobald、David Vesey、Daryl S. Walter、Gareth Wayne

  DOI：10.1021/jm800138h

  日期：2008.6.1

  BACE-1 inhibition has the potential to provide a disease-modifying therapy for the treatment of Alzheimer's disease. Optimization of a first generation of BACE-1 inhibitors led to the discovery of novel hydroxyethylamines (HEAs) bearing a tricyclic nonprime side. These derivatives have nanomolar cell potency and are orally bioavailable.
• Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent
  作者：Nicolas Charrier、Brian Clarke、Emmanuel Demont、Colin Dingwall、Rachel Dunsdon、Julie Hawkins、Julia Hubbard、Ishrut Hussain、Graham Maile、Rosalie Matico、Julie Mosley、Alan Naylor、Alistair O’Brien、Sally Redshaw、Paul Rowland、Virginie Soleil、Kathrine J. Smith、Sharon Sweitzer、Pam Theobald、David Vesey、Daryl S. Walter、Gareth Wayne

  DOI：10.1016/j.bmcl.2009.03.150

  日期：2009.7

  Our first generation of hydroxyethylamine transition-state mimetic BACE-1 inhibitors allowed us to validate BACE-1 as a key target for Alzheimer's disease by demonstrating amyloid lowering in an animal model, albeit at rather high doses. Finding a molecule from this series which was active at lower oral doses proved elusive and demonstrated the need to find a novel series of inhibitors with improved pharmacokinetics. This Letter describes the discovery of such inhibitors.